Journal of Digestive Cancer Reports

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지

The Metformin Use and Gastric Cancer Risk

메트포르민의 사용과 위암 발생

  • Kim, Young-Il (Center for Gastric Cancer, National Cancer Center)
  • Received : 2020.11.05
  • Accepted : 2020.11.17
  • Published : 2020.12.31

⟨ Previous Next ⟩

Abstract

Metformin is a widely used first-line anti-diabetic drug worldwide. Epidemiologic studies using the large population-based cohort database have shown the association between metformin uses and reduced risk of various type cancers including gastric cancer. In the gastric cancer prevention, metformin use was associated with the significant reduction of gastric cancer risk, especially for long-term metformin users. However, there is no well-designed randomized controlled clinical trial investigating the effect of metformin as a chemopreventive drug for gastric cancer. Therefore, further well-designed clinical trials will be needed to implement metformin for chemoprevention of gastric cancer.

Keywords

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. https://doi.org/10.3322/caac.21492
  2. Hong S, Won YJ, Park YR, Jung KW, Kong HJ, Lee ES. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat 2020;52:335-350. https://doi.org/10.4143/crt.2020.206
  3. Schistosomes, liver flukes and Helicobacter pylori. IARC working group on the evaluation of carcinogenic risks to humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994;61:1-241.
  4. Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ 2014;348:g3174. https://doi.org/10.1136/bmj.g3174
  5. Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori Therapy for the prevention of metachronous gastric cancer. N Engl J Med 2018;378:1085-1095. https://doi.org/10.1056/NEJMoa1708423
  6. Choi IJ, Kim CG, Lee JY, et al. Family history of gastric cancer and helicobacter pylori treatment. N Engl J Med 2020;382:427-436. https://doi.org/10.1056/NEJMoa1909666
  7. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-194. https://doi.org/10.1001/jama.291.2.187
  8. Chen HN, Wang Z, Li X, Zhou ZG. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a metaanalysis. Gastric Cancer 2016;19:166-175. https://doi.org/10.1007/s10120-015-0462-7
  9. Wu XD, Zeng K, Xue FQ, Chen JH, Chen YQ. Statins are associated with reduced risk of gastric cancer: a meta-analysis. Eur J Clin Pharmacol 2013;69:1855-1860. https://doi.org/10.1007/s00228-013-1547-z
  10. Bosetti C, Santucci C, Gallus S, Martinetti M, La Vecchia C. Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019. Ann Oncol 2020;31:558-568. https://doi.org/10.1016/j.annonc.2020.02.012
  11. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PloS ONE 2013;8:e71583. https://doi.org/10.1371/journal.pone.0071583
  12. Americal Diabetes Association. 8. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care 2017;40:S64-S74. https://doi.org/10.2337/dc17-S011
  13. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia 2017;60:1577-1585. https://doi.org/10.1007/s00125-017-4342-z
  14. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-1305. https://doi.org/10.1136/bmj.38415.708634.f7
  15. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a populationbased cohort study. Am J Gastroenterol 2012;107:46-52. https://doi.org/10.1038/ajg.2011.384
  16. Ruiter R, Visser LE, van Herk-Sukel MP, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care 2012;35:119-124. https://doi.org/10.2337/dc11-0857
  17. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-1625. https://doi.org/10.2337/dc08-2175
  18. van Staa TP, Patel D, Gallagher AM, de Bruin ML. Glucoselowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia 2012;55:654-665. https://doi.org/10.1007/s00125-011-2390-3
  19. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC cancer 2011;11:20. https://doi.org/10.1186/1471-2407-11-20
  20. Kim YI, Kim SY, Cho SJ, et al. Long-term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment: a nationwide cohort study. Aliment Pharmacol Thera 2014;39:854-863. https://doi.org/10.1111/apt.12660
  21. Valent F. Diabetes mellitus and cancer of the digestive organs: An Italian population-based cohort study. J Diabetes Complications 2015;29:1056-1061. https://doi.org/10.1016/j.jdiacomp.2015.07.017
  22. Tseng CH. Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus. Aging 2016;8:1636-1649. https://doi.org/10.18632/aging.101019
  23. Steward WP, Brown K. Cancer chemoprevention: a rapidly evolving field. Br J Cancer 2013;109:1-7. https://doi.org/10.1038/bjc.2013.280
  24. Morse MA, Stoner GD. Cancer chemoprevention: principles and prospects. Carcinogenesis 1993;14:1737-1746. https://doi.org/10.1093/carcin/14.9.1737
  25. Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012;35:731-737. https://doi.org/10.2337/dc11-1299
  26. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006:CD002967.
  27. Daugan M, Dufay Wojcicki A, d'Hayer B, Boudy V. Metformin: An anti-diabetic drug to fight cancer. Pharmacol Res 2016;113:675-685. https://doi.org/10.1016/j.phrs.2016.10.006
  28. Vijg J, Campisi J. Puzzles, promises and a cure for ageing. Nature 2008;454:1065-1071. https://doi.org/10.1038/nature07216
  29. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-10273. https://doi.org/10.1158/0008-5472.CAN-06-1500
  30. Pietrocola F, Kroemer G. Metformin: a metabolic modulator. Oncotarget 2017;8:9017-9020. https://doi.org/10.18632/oncotarget.14794
  31. Del Barco S, Vazquez-Martin A, Cufi S, et al. Metformin: multi-faceted protection against cancer. Oncotarget 2011;2:896-917. https://doi.org/10.18632/oncotarget.387
  32. Jalving M, Gietema JA, Lefrandt JD, et al. Metformin: taking away the candy for cancer? Eur J Cancer 2010;46:2369-2380. https://doi.org/10.1016/j.ejca.2010.06.012
  33. Ersoy C, Kiyici S, Budak F, et al. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res Clin Pract 2008;81:56-60. https://doi.org/10.1016/j.diabres.2008.02.006
  34. Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008;27:3576-3586. https://doi.org/10.1038/sj.onc.1211024
  35. Kato K, Gong J, Iwama H, et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther 2012;11:549-560. https://doi.org/10.1158/1535-7163.MCT-11-0594
  36. Yu G, Fang W, Xia T, et al. Metformin potentiates rapamycin and cisplatin in gastric cancer in mice. Oncotarget 2015;6:12748-12762. https://doi.org/10.18632/oncotarget.3327
  37. Zhuang S, Jian Y, Sun Y. Metformin inhibits N-Methyl-NNitrosourea induced gastric tumorigenesis in db/db mice. Exp Clin Endocrinol Diabetes 2017;125:392-399. https://doi.org/10.1055/s-0043-100118
  38. Valaee S, Yaghoobi MM, Shamsara M. Metformin inhibits gastric cancer cells metastatic traits through suppression of epithelial-mesenchymal transition in a glucose-independent manner. PloS ONE 2017;12:e0174486. https://doi.org/10.1371/journal.pone.0174486
  39. Kim J, Hyun HJ, Choi EA, Kim Y, Bae YJ, Kang HT. Metformin use reduced the risk of stomach cancer in diabetic patients in Korea: an analysis of Korean NHIS-HEALS database. Gastric Cancer 2020;23:1075-1083. https://doi.org/10.1007/s10120-020-01085-1